Aclaris Therapeutics
158 articles about Aclaris Therapeutics
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
2/27/2024
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.
-
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
1/16/2024
Aclaris Therapeutics, Inc. announced leadership changes and that it is undertaking a strategic review of its business.
-
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
1/10/2024
Aclaris Therapeutics, Inc. today announced top-line results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (AD) (ATI-1777-AD-202; NCT05432596).
-
Aclaris Therapeutics Provides Corporate Update
12/19/2023
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.
-
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
12/5/2023
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc.
-
Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II study for rheumatoid arthritis.
-
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
11/13/2023
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced top-line results from a Phase 2b study of zunsemetinib, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.
-
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
11/6/2023
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced its financial results for the third quarter of 2023 and provided a corporate update.
-
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
10/3/2023
Aclaris Therapeutics, Inc. today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis.
-
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
9/20/2023
Aclaris Therapeutics, Inc. today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY.
-
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
9/18/2023
Aclaris Therapeutics, Inc. today announced positive results from ATI-2138-PKPD-102, a Phase 1 Multiple Ascending Dose (MAD) trial of the investigational compound ATI-2138.
-
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
8/7/2023
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced its financial results for the second quarter of 2023 and provided a corporate update.
-
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
6/13/2023
Aclaris Therapeutics, Inc. announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis.
-
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
6/2/2023
Aclaris Therapeutics, Inc. today announced that members of the Aclaris management team will participate in two healthcare investor conferences in June.
-
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
5/8/2023
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2023 and provided a corporate update.
-
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
3/27/2023
Aclaris Therapeutics, Inc. today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET.
-
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
3/6/2023
Aclaris Therapeutics, Inc. today announced preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, placebo-controlled clinical study to investigate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in patients with moderate to severe hidradenitis suppurativa (HS) (ATI-450-HS-201).
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
2/23/2023
Aclaris Therapeutics, Inc. today announced its financial results for the fourth quarter and full year of 2022 and provided a corporate update.
-
Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference
2/9/2023
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 9:20 AM ET.
-
Aclaris Therapeutics Provides 2023 Outlook
1/6/2023
Aclaris Therapeutics, Inc. today is providing a corporate outlook for 2023.